mark kris, md: antiangiogenic therapy in nsclc
Published 8 years ago • 57 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
1:39
mark kris, md: choosing a treatment in nsclc
-
2:05
mark socinski, md: antiangiogenic therapy in nsclc
-
1:14
dr. kris discusses role of antiangiogenesis in lung cancer
-
1:45
mark kris, md: lacking actionable mutations in nsclc
-
1:57:39
session 3 - introduction to imrt treatments
-
2:24
how targeted therapy works | central principles of molecular biology
-
2:29
what is targeted therapy in cancer? - dr. ankur bahl explains
-
6:11
how does antiangiogenic therapy work?
-
3:02
using antiangiogenic therapy in stage 4 nsclc
-
2:07
using antiangiogenic therapy in nsclc in the future
-
1:48
dr. mark kris on immunotherapy and frontline options for patients with nsclc
-
9:12
the current role for antiangiogenic therapy for nsclc
-
3:05
rationale behind antiangiogenic therapy in nsclc
-
1:28
dr. kris on the future of immunotherapy and targeted therapy in lung cancer
-
1:25
mark kris on new therapies for lung cancer
-
1:54
dr. mark kris on the combination of molecularly targeted therapies
-
5:53
targeted therapy in non-small cell lung cancer
-
0:31
dr. kris discusses available targeted therapies
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
4:56
what are treatment guidelines? with mark kris, md
-
4:18
asco data present 'clear roadmap' to treat locally advanced nsclc
-
9:41
immunotherapy with antiangiogenics in nsclc